As per the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of US patent 7,935,528.
The patent covers the methods to isolate and use human liver stem cells to treat degenerative liver diseases, or inherited deficiencies of liver function.
MultiCell chairman and CEO Gerald Newmin said they are pleased the USPTO has agreed that their liver stem cells are indeed novel and may lead to important therapeutic applications.
"Our efforts to better understand liver stem cell biology, and the role these cells play in chronic liver disease and primary hepatocellular carcinoma, is a major focus of the Company," Newmin said.